Vertex announces positive results from the vx-548 phase 3 program for the treatment of moderate-to-severe acute pain

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced positive results from its phase 3 program for the selective nav1.8 inhibitor, vx-548, in the treatment of moderate-to-severe acute pain. the phase 3 program included two randomized, double-blind, placebo-controlled, pivotal trials, one following abdominoplasty surgery and one following bunionectomy surgery, as well as a single arm safety and effectiveness study which enrolled patients with a broad range.
VRTX Ratings Summary
VRTX Quant Ranking